Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Video

Transcript:

Related Videos
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Nan Chen, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Julia Foldi, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Related Content
Lora Markley, Director of Regional Managed Care for The US Oncology Network

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
FDA

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024
Article
Elizabeth Plimack, MD, MS, FASCO

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024
Article